bluuebunny/crossref_metadata_2025_split huggingface dataset:
Efficacy and safety of a neurointerventional operation robotic assistance system in cerebral angiography
Authors: Liu He , Li Conghui , Ren Shaohua , Li Tong , Zhong Hongliang , Jia Jianwen , Yang Hongchao , Qi Yi , Feng Junqiang , Li Youxiang , Wang Yang 
Published: September 2023

Background
At present, neurointerventional surgery requires angiographers to perform operations in the digital subtraction angiography (DSA) room. Ionising radiation and chronic joint damage are still unavoidable for angiographers. Therefore, we researched and developed a neurointerventional robot-assisted system, which is operated by angiographers in an operating room outside the DSA room. We have conducted a prospective, multicentre, randomised controlled trial to evaluate the safety and efficacy of a robot-assisted system in human cerebral angiography. In the future, this research will provide a platform for the research and development of an intelligent surgical system and bring revolutionary progress in neurointerventional surgery.

Methods
From December 2020 to December 2021, 260 patients were enrolled from three medical centres, who were randomly and equally divided into a robot-assisted system group and a clinical routine cerebral angiography group. The success rate of angiography, the rate of the catheter reaching the target vessel, the operation time, X-ray radiation exposure and the incidence of related adverse events were compared between the two groups.

Results
A total of 257 patients completed this trial; baseline characteristics of the two groups did not differ significantly. The success rate of angiography in both the control group and the experimental group was 100%. The rate of the catheter reaching the target vessel was 99.23% and 100.00% in the control and experimental groups, respectively. For the control versus experimental groups, the angiographic operation time was 48.59±25.60 min versus 47.94±27.49 min, respectively; the X-ray radiation dose was 735.01±554.77 mGy versus 821.65±705.45 mGy, respectively; and the incidence of adverse events was 23.44% versus 22.48%, respectively. No statistical differences were present between the two groups.

Conclusion
The robot-assisted surgical system is more convenient for cerebral angiography and is as safe and effective as the traditional cerebral angiography.
Combined computed tomography and C-arm resuscitation room system (CTCARM) is associated with decreased time to definitive hemostasis and reduces preperitoneal pelvic packing maneuvers in severe pelvic trauma
Authors: Uchida Kenichiro , Deguchi Ryo , Himura Hoshi , Yoshitake Hiroyuki , Kawamoto Akihiro , Saoyama Yuki , Miyashita Masahiro , Nishimura Tetsuro , Yamamoto Hiromasa , Mizobata Yasumitsu 
Published: September 2023

ObjectivesSevere pelvic fracture concomitant with massive bleeding is potentially lethal, and intervention for hemorrhage control still depends on institutional supplies. With the recent installation of a CT and C-arm combined resuscitation room system (CTCARM) for treatment of trauma patients in our institution, the strategic process and options for hemorrhage control after pelvic fracture have changed. We retrospectively reviewed the procedures we performed and their outcomes.MethodsThe CTCARM was installed in our trauma resuscitation room in April 2020. Patients who were diagnosed as having pelvic fracture and underwent interventional radiology for hemorrhage control within 2.5 hours after arrival were compared before and after CTCARM installation. We reviewed the time process for hemorrhage control, treatment options performed, blood products used and their outcomes.ResultsIncluded in this study were 56 patients treated between 2016 and 2022, of whom 36 patients were treated before (original group) and 20 patients after CTCARM installation (CTCARM group). Patient characteristics and vital signs at admission were not statistically different. Preperitoneal pelvic packing was performed significantly more frequently in the original group (p<0.01), whereas resuscitative endovascular balloon occlusion of the aorta use was much more frequent in the CTCARM group (p=0.02). Although the times from admission to first angiography (p=0.014) and to complete hemostasis (p=0.02) were significantly shorter in the CTCARM group, mortality was not statistically different. Four preventable trauma deaths occurred in the original group, but there were none in the CTCARM group. Six unexpected survivors were observed in the original group and four in the CTCARM group.ConclusionsAlthough the CTCARM had no direct effects on patient mortality for now, it has allowed us to accelerate the treatment time process, shorten preperitoneal pelvic packing procedural time, and potentially avoid subsequent preventable trauma deaths.Level of evidenceLevel IV.
Complementarity of $$B\rightarrow K^{(*)} \mu \bar{\mu }$$ and $$B\rightarrow K^{(*)} + \textrm{inv}$$ for searches of GeV-scale Higgs-like scalars
Authors: Ovchynnikov Maksym , Schmidt Michael A. , Schwetz Thomas 
Published: September 2023

AbstractThe rare decays $$B^+\rightarrow K^+ \mu \bar{\mu }$$

B
+

→

K
+

μ

μ

¯

and $$B^0\rightarrow K^{*0} \mu \bar{\mu }$$

B
0

→

K

∗
0

μ

μ

¯

provide the strongest constraints on the mixing of a light scalar with the Higgs boson for GeV-scale masses. The constraints sensitively depend on the branching ratio to muons. Additional decay channels like an invisible partial width may substantially weaken the constraints. This scenario will be probed at Belle II in $$B\rightarrow K^{(*)} + \textrm{inv}$$

B
→

K

(

∗
)

+
inv

. We illustrate the complementarity of scalar decays to muons and invisible decays using the currently available results of LHCb and BaBar. We provide two simple model realisations providing a sizeable invisible scalar width, one based on a real scalar and one based on a $$U(1)_{B-L}$$

U

(
1
)

B
-
L

gauge symmetry. In both examples the scalar decays into heavy neutral leptons which can be motivated by the seesaw mechanism for neutrino masses.
Applicability of the 0–1 test for chaos in magnetized Kerr–Newman spacetimes
Authors: Yang Daqi , Wu Xin 
Published: September 2023

AbstractThe dynamics of electrically neutral or charged particles around a magnetized Kerr–Newman black hole immersed in an external electromagnetic field can be described by a dimensionless Hamiltonian system. This Hamiltonian is given an appropriate time transformation, which allows for construction of explicit symplectic integrators. Selecting one of the integrators with good accuracy, long-term stabilized Hamiltonian error behavior and less computational cost, we employ the 0–1 binary test correlation method to distinguish between regular and chaotic dynamics of electrically neutral or charged particles. The correlation method is almost the same as the techniques of Poincaré map and fast Lyapunov indicators in identifying the regular and chaotic two cases. It can well describe the dependence of the transition from regularity to chaos on varying one or two dynamical parameters. From a statistical viewpoint, chaos occurs easily under some circumstances with an increase of the external magnetic field strength and the particle electric charge and energy or a decrease of the black hole spin and the particle angular momentum. A small change of the black hole electric charge does not very sensitively affect the dynamics of neutral particles. With the black hole electric charge increasing, positively charged particles do not easily yield chaotic motions, but negatively charged particles do. On the other hand, the effect of a small change of the black hole magnetic charge on the dynamical transition from order to chaos has no universal rule.
Combined Shallow and Deep Learning Models for Malware Detection in Wsn
Authors: Chandan Madhavarapu , Santhi S. G. , Srinivasa Rao T. 
Published: September 2023

Due to the major operating restrictions, ensuring security is the fundamental problem of Wireless Sensor Networks (WSNs). Because of their inadequate security mechanisms, WSNs are indeed a simple point for malware (worms, viruses, malicious code, etc.). According to the epidemic nature of worm propagation, it is critical to develop a worm defense mechanism in the network. This concept aims to establish novel malware detection in WSN that consists of several phases: “(i) Preprocessing, (ii) feature extraction, as well as (iii) detection”. At first, the input data is subjected for preprocessing phase. Then, the feature extraction takes place, in which principal component analysis (PCA), improved linear discriminant analysis (LDA), and autoencoder-based characteristics are retrieved. Moreover, the retrieved characteristics are subjected to the detection phase. The detection is performed employing combined shallow learning and DL. Further, the shallow learning includes decision tree (DT), logistic regression (LR), and Naive Bayes (NB); the deep learning (DL) includes deep neural network (DNN), convolutional neural network (CNN), and recurrent neural network (RNN). Here, the DT output is given to the DNN, LR output is subjected to CNN, and the NB output is given to the RNN, respectively. Eventually, the DNN, CNN, and RNN outputs are averaged to generate a successful outcome. The combination can be thought of as an Ensemble classifier. The weight of the RNN is optimally tuned through the Self Improved Shark Smell Optimization with Opposition Learning (SISSOOL) model to improve detection precision and accuracy. Lastly, the outcomes of the suggested approach are computed in terms of different measures.
Epidemiology of Oral Human Papillomavirus Infection among Diverse Chinese Adults in Typical Areas of China: Findings from the DLCC Study
Authors: Zhu Yingying , He Huijing , Zhu Xiaoli , Hu Yaoda , Yu Shuting , Diao Wenwen , Li Shuguang , Shan Guangliang , Chen Xingming 
Published: September 2023

Abstract

Background:
Human papillomavirus (HPV) infection is a predominant cause of oropharyngeal squamous cell carcinoma. However, there is limited knowledge about the epidemiology of oral HPV infections among adults in China.

Methods:
We collected data from a prospective cohort that enrolled participants in Mainland China. A total of 9,867 participants ages at least 20 years provided oral swab specimens in typical areas of China (Hebei and Guangdong provinces) in 2021. HPV DNA in oral exfoliated cells was tested using nested PCR and sequencing. Prevalence among subpopulations was compared. Multivariable logistic regression models were employed to assess possible factors influencing oral HPV infection.

Results:
The overall prevalence of oral HPV infection was 3.0% [95% confidence interval (CI): 2.68–3.36]. Among those infected, 1.3% (1.08–1.53) were infected with high-risk HPV types. Men had a higher age-standardized HPV infection prevalence (3.6%, 2.96–4.29) compared with their female counterparts (2.7%, 2.35–3.12). People in Hebei had a higher age- and sex-standardized prevalence (4.1%, 3.50–4.70) than those in Guangdong (2.2%, 1.80–2.56). Generally, men (OR and 95% CI: 1.42, 1.09–1.85) and people in Hebei (2.01, 1.53–2.65) had higher odds of any type of HPV infection. In addition, people living in urban areas had a 2.15-fold (1.43–3.26) higher odds of high-risk HPV infection.

Conclusions:
This study reveals a low prevalence of oral HPV infection with significant geographic and sex differences among Chinese population.

Impact:
This is the first study to report the epidemiologic characteristics of oral HPV infection among Chinese adults in diverse geographic areas with large sample size.
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
Authors: Patel Timil H. , Brewer Jamie R. , Fan Jiaxin , Cheng Joyce , Shen Yuan-Li , Xiang Yue , Zhao Hong , Lemery Steven J. , Pazdur Richard , Kluetz Paul G. , Fashoyin-Aje Lola A. 
Published: September 2023

Abstract
On October 21, 2022, the FDA approved tremelimumab (Imjudo) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma. The approval was based on the results from the HIMALAYA study, in which patients with unresectable hepatocellular carcinoma who were naïve to previous systemic treatment were randomly assigned to receive one of three study arms: tremelimumab in combination with durvalumab (n = 393), durvalumab (n = 389), or sorafenib (n = 389). The primary objective of improvement in overall survival (OS) for tremelimumab in combination with durvalumab compared with sorafenib met statistical significance with a stratified HR of 0.78 [95% confidence interval (CI), 0.66–0.92; P = 0.0035]. The median OS was 16.4 months (95% CI, 14.2–19.6) with tremelimumab in combination with durvalumab and 13.8 months (95% CI, 12.3–16.1) with sorafenib. Adverse reactions occurring in ≥20% of patients receiving tremelimumab in combination with durvalumab were rash, fatigue, diarrhea, pruritus, musculoskeletal pain, and abdominal pain. The recommended tremelimumab dose for patients weighing 30 kg or more is 300 mg, i.v., as a single dose in combination with durvalumab 1,500 mg at cycle 1/day 1, followed by durvalumab 1,500 mg, i.v., every 4 weeks. For those weighing less than 30 kg, the recommended tremelimumab dose is 4 mg/kg, i.v., as a single dose in combination with durvalumab 20 mg/kg, i.v., followed by durvalumab 20 mg/kg, i.v., every 4 weeks.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
Authors: Mutlu Levent , Manavella Diego D. , Bellone Stefania , McNamara Blair , Harold Justin A. , Mauricio Dennis , Siegel Eric R. , Buza Natalia , Hui Pei , Hartwich Tobias Max Philipp , Yang-Hartwich Yang , Demirkiran Cem , Verzosa Miguel Skyler Z. , Altwerger Gary , Ratner Elena S. , Huang Gloria S. , Clark Mitchell , Andikyan Vaagn , Azodi Masoud , Dottino Peter R. , Schwartz Peter E. , Santin Alessandro D. 
Published: September 2023

Abstract
Uterine serous carcinoma (USC) is a rare, biologically aggressive variant of endometrial cancer with a high recurrence rate and poor prognosis. HER2 overexpression (3+ positivity) by IHC and/or FISH ERBB2 gene amplification is detected in approximately one-third of patients with USC. Clinical trials incorporating trastuzumab with standard chemotherapy have recently demonstrated improved progression-free and overall survival in advanced-stage or recurrent USC that overexpresses HER2. However, a large number of patients with USC eventually developed resistance to trastuzumab. Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody–drug conjugate with a topoisomerase I inhibitor payload recently approved by the Food and Drug Administration (FDA) for multiple tumor indications. Here, we investigated the in vitro and in vivo efficacy of T-DXd in primary USC cell lines and xenografts with different HER2 expression. T-DXd–induced cell growth suppression in HER2-overexpressing cell lines in vitro, increased early and late apoptosis as assessed by annexin and propidium iodide staining, and, similarly to trastuzumab, T-DXd–induced significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes. While negligible activity was detected against USC cell lines with low HER2 expression, T-DXd demonstrated significant bystander killing against USC tumors with low/negligible HER2 when such cells were admixed with HER2 3+ tumor cells in vitro. T-DXd showed tumor growth suppression in in vivo USC PDX models that overexpress HER2 at 3+ levels, prolonging survival when compared with controls, with minimal toxicity. Future clinical trials are warranted in patients with USC failing trastuzumab treatment.
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
Authors: Alečković Maša , Li Zheqi , Zhou Ningxuan , Qiu Xintao , Lulseged Bethlehem , Foidart Pierre , Huang Xiao-Yun , Garza Kodie , Shu Shaokun , Kesten Nikolas , Li Rong , Lim Klothilda , Garrido-Castro Ana C. , Guerriero Jennifer L. , Qi Jun , Long Henry W. , Polyak Kornelia 
Published: September 2023

AbstractImmune checkpoint inhibition combined with chemotherapy is currently approved as first-line treatment for patients with advanced PD-L1–positive triple-negative breast cancer (TNBC). However, a significant proportion of metastatic TNBC is PD-L1–negative and, in this population, chemotherapy alone largely remains the standard-of-care and novel therapeutic strategies are needed to improve clinical outcomes. Here, we describe a triple combination of anti-PD-L1 immune checkpoint blockade, epigenetic modulation thorough bromodomain and extra-terminal (BET) bromodomain inhibition (BBDI), and chemotherapy with paclitaxel that effectively inhibits both primary and metastatic tumor growth in two different syngeneic murine models of TNBC. Detailed cellular and molecular profiling of tumors from single and combination treatment arms revealed increased T- and B-cell infiltration and macrophage reprogramming from MHCIIlow to a MHCIIhigh phenotype in mice treated with triple combination. Triple combination also had a major impact on gene expression and chromatin profiles shifting cells to a more immunogenic and senescent state. Our results provide strong preclinical evidence to justify clinical testing of BBDI, paclitaxel, and immune checkpoint blockade combination.
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
Authors: Santasusagna Sandra , Zhu Shijia , Jawalagatti Vijayakumar , Carceles-Cordon Marc , Ertel Adam , Garcia-Longarte Saioa , Song Won-Min , Fujiwara Naoto , Li Peiyao , Mendizabal Isabel , Petrylak Daniel P. , Kelly William Kevin , Reddy E. Premkumar , Wang Liguo , Schiewer Matthew J. , Lujambio Amaia , Karnes Jeffrey , Knudsen Karen E. , Cordon-Cardo Carlos , Dong Haidong , Huang Haojie , Carracedo Arkaitz , Hoshida Yujin , Rodriguez-Bravo Veronica , Domingo-Domenech Josep 
Published: September 2023

Abstract

Signaling rewiring allows tumors to survive therapy. Here we show that the decrease of the master regulator microphthalmia transcription factor (MITF) in lethal prostate cancer unleashes eukaryotic initiation factor 3B (eIF3B)–dependent translation reprogramming of key mRNAs conferring resistance to androgen deprivation therapy (ADT) and promoting immune evasion. Mechanistically, MITF represses through direct promoter binding eIF3B, which in turn regulates the translation of specific mRNAs. Genome-wide eIF3B enhanced cross-linking immunoprecipitation sequencing (eCLIP-seq) showed specialized binding to a UC-rich motif present in subsets of 5′ untranslated regions. Indeed, translation of the androgen receptor and major histocompatibility complex I (MHC-I) through this motif is sensitive to eIF3B amount. Notably, pharmacologic targeting of eIF3B-dependent translation in preclinical models sensitizes prostate cancer to ADT and anti–PD-1 therapy. These findings uncover a hidden connection between transcriptional and translational rewiring promoting therapy-refractory lethal prostate cancer and provide a druggable mechanism that may transcend into effective combined therapeutic strategies.

Significance:
Our study shows that specialized eIF3B-dependent translation of specific mRNAs released upon downregulation of the master transcription factor MITF confers castration resistance and immune evasion in lethal prostate cancer. Pharmacologic targeting of this mechanism delays castration resistance and increases immune-checkpoint efficacy.
This article is featured in Selected Articles from This Issue, p. 2489
Low-Cost High-Throughput Genotyping for Diagnosing Familial Hypercholesterolemia
Authors: Ibrahim Shirin , van Rooij Jeroen , Verkerk Annemieke J.M.H. , de Vries Jard , Zuurbier Linda , Defesche Joep , Peter Jorge , Schonck Willemijn A.M. , Sedaghati-Khayat Bahar , Kees Hovingh G. , Uitterlinden André G. , Stroes Erik S.G. , Reeskamp Laurens F. 
Published: September 2023

BACKGROUND:
Familial hypercholesterolemia (FH) is a common but underdiagnosed genetic disorder characterized by high low-density lipoprotein cholesterol levels and premature cardiovascular disease. Current sequencing methods to diagnose FH are expensive and time-consuming. In this study, we evaluated the accuracy of a low-cost, high-throughput genotyping array for diagnosing FH.

METHODS:
An Illumina Global Screening Array was customized to include probes for 636 variants, previously classified as FH-causing variants. First, its theoretical coverage was assessed in all FH variant carriers diagnosed through next-generation sequencing between 2016 and 2022 in the Netherlands (n=1772). Next, the performance of the array was validated in another sample of FH variant carriers previously identified in the Dutch FH cascade screening program (n=1268).

RESULTS:

The theoretical coverage of the array for FH-causing variants was 91.3%. Validation of the array was assessed in a sample of 1268 carriers of whom 1015 carried a variant in
LDLR
, 250 in
APOB
, and 3 in
PCSK9
. The overall sensitivity was 94.7% and increased to 98.2% after excluding participants with variants not included in the array design. Copy number variation analysis yielded a 89.4% sensitivity. In 18 carriers, the array identified a total of 19 additional FH-causing variants. Subsequent DNA analysis confirmed 5 of the additionally identified variants, yielding a false-positive result in 16 subjects (1.3%).

CONCLUSIONS:
The FH genotyping array is a promising tool for genetically diagnosing FH at low costs and has the potential to greatly increase accessibility to genetic testing for FH. Continuous customization of the array will further improve its performance.